HeroBanner1_Home Hero1 mobile image

Creating the world's most durable heart valve

 

BETTER SCIENCE.

BETTER DESIGN.

  

 

Live in the OR Interview

Anteris CEO Wayne Paterson

Interview with the implanting physicians from the DurAVR First-in-Human Study

  

POWERED BY SCIENCE. DEVELOPED BY EXPERTS.

Engineered to deliver the most durable heart valve for patients with severe aortic stenosis - DurAVR™ Transcatheter Heart Valve elevates science and enhances the human life.

Learn More

  

INSPIRED BY HUMANS
EMPOWERED BY PURPOSE.

Anteris Technologies is a Structural Heart Company committed to discovering, developing, and delivering a pipeline of innovative medical device solutions that aim to improve the health outcomes of patient populations and dramatically improve people's lives.

   

INVESTOR CENTER

We drive awareness and adoption of our ADAPT technology through our key partnerships while attracting the best talent, fostering a culture of agility, creativity, quality, and excellence. We apply scientific curiosity and innovative thinking to deliver transformative solutions to patients.

Learn More
button

LATEST ANTERIS NEWS

Tile1 TILE1 MOBILE

Breaking News
DurAVR™ THV EFS

US FDA has granted expanded approval
Unconditionally Approved

Feburary 2023

ASX Announcement
tile2 Desktop image tile1 mobile

PCR London Valves: Expert Interview

DurAVR THV Impact of Novel Leaflet Design on Hemodynamics and Physiology

Presented by:

Faculty: Bernard Prendergast, MD
Joao Cavalcante, MD, and Chris Meduri, MD
Watch Here
tile3desktop mobtile3

PCR London Valves: Late Breaking Clinical Trial

DurAVR THV First-in-Human Study, 30-day Results
Presented by Chris Meduri, MD
Karolinska University Medical Center, Sweden

 

View Here
tile4 desktop mobtile4

TCT 2022 DurAVR™ THV - Interview with TAVR Experts

Shaping TAVR of the Future: Anteris Tech’s DurAVR™ Transcatheter Heart Valve

Presented by:
Moderator: Martin B. Leon, MD
Faculty: Rebecca Hahn, MD, Chris Meduri, MD,
Thomas Modine, MD, and Michael Reardon, MD
Watch Here